Moderna expands COVID-19 vaccine supply agreement with U.K.

By The Science Advisory Board staff writers

November 30, 2020 -- Moderna has announced a supply agreement with the U.K. government for an additional 2 million doses of messenger RNA (mRNA)-1273, the company's COVID-19 vaccine, beginning in March 2021.

The U.K. government has now secured 7 million doses of Moderna's vaccine. Moderna is scaling up its global manufacturing to be able to deliver approximately 500 million doses per year and possibly up to 1 billion doses per year beginning in 2021. The firm is working with Lonza of Switzerland and ROVI of Spain for manufacturing and fill-finish processing outside the U.S.

Moderna to file COVID-19 vaccine EUA request
Moderna said it plans to request on November 30 an emergency use authorization (EUA) from the U.S. Food and Drug Administration and conditional marketing...
EC secures 80M doses of Moderna COVID-19 vaccine
Moderna has announced that the European Commission (EC) has agreed to secure 80 million doses of its COVID-19 vaccine messenger RNA (mRNA)-1273.
EU secures 225M doses of CureVac COVID-19 vaccine
The European Commission approved a fifth contract with CureVac for the initial purchase of 225 million doses on behalf of all European Union (EU)...
Moderna reports EMA review of COVID-19 vaccine candidate, U.K. supply deal
Moderna said that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use has initiated a rolling review of the firm's messenger...
Moderna reports 94.5% efficacy for COVID-19 vaccine
A COVID-19 vaccine under development by Moderna had 94.5% efficacy in a phase III clinical trial, according to an independent data safety monitoring board...

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter